108 related articles for article (PubMed ID: 23461012)
1. [Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].
Belonovskaia EB; Naruta EE; Lukivskaia OIa; Abakumov VZ; Buko VU
Eksp Klin Farmakol; 2013; 76(1):25-9. PubMed ID: 23461012
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Lukivskaya O; Zavodnik L; Knas M; Buko V
Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
[TBL] [Abstract][Full Text] [Related]
3. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver.
Lukivskaya OY; Maskevich AA; Buko VU
Alcohol; 2001 Oct; 25(2):99-105. PubMed ID: 11747979
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Ali MH; Messiha BA; Abdel-Latif HA
Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.
Ishizaki K; Iwaki T; Kinoshita S; Koyama M; Fukunari A; Tanaka H; Tsurufuji M; Sakata K; Maeda Y; Imada T; Chiba K
Eur J Pharmacol; 2008 Jan; 578(1):57-64. PubMed ID: 17888421
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
8. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholate alleviates alcoholic fatty liver damage in rats.
Oliva L; Beaugé F; Choquart D; Montet AM; Guitaoui M; Montet JC
Alcohol Clin Exp Res; 1998 Oct; 22(7):1538-43. PubMed ID: 9802540
[TBL] [Abstract][Full Text] [Related]
10. Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats.
Nowak G; Norén UG; Wernerson A; Marschall HU; Möller L; Ericzon BG
Transpl Int; 2005 May; 17(12):804-9. PubMed ID: 15815896
[TBL] [Abstract][Full Text] [Related]
11. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
[TBL] [Abstract][Full Text] [Related]
12. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
13. The protective effect of ursodeoxycholic acid in alloxan-induced diabetes.
Lukivskaya O; Lis R; Egorov A; Naruta E; Tauschel HD; Buko VU
Cell Biochem Funct; 2004; 22(2):97-103. PubMed ID: 15027098
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
[TBL] [Abstract][Full Text] [Related]
16. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
17. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.
Lim SC; Duong HQ; Choi JE; Lee TB; Kang JH; Oh SH; Han SI
Carcinogenesis; 2011 May; 32(5):723-31. PubMed ID: 21362627
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]